ADVA unveils market’s first high-performance optical cesium clock
ADVA (FSE: ADV) today achieved an industry first with the introduction of its Oscilloquartz high-performance optical cesium atomic clock. The coreSync™ OSA 3300-HP is ADVA’s latest innovation in assured PNT, ushering in a new age of precise synchronization with unprecedented stability. Following ADVA’s launch of the first optical pumping timing solution two years ago, the OSA 3350 ePRC+, the OSA 3300-HP takes the technology to new levels. It has a 10-year lifetime compared to the five years offered by currently available high-performance magnetic clocks. As the market’s only high-performance optical cesium clock, the OSA 3300-HP sets a new benchmark for precision and availability, providing the resilience required for PNT assurance in critical infrastructure and empowering service providers to deliver differentiated SLA timing offerings with integrated GNSS backup. The feature-rich device has embedded Ethernet- and IP-based management as well as a user-friendly touchscreen GUI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005667/en/
ADVA’s OSA 3300-HP is a major milestone for high-performance optical cesium technology. (Photo: Business Wire)
“The launch of our coreSync™ OSA 3300-HP marks a key milestone in the design of atomic frequency and phase standards. After many years of extensive work in our Swiss laboratories supported by the European Space Agency, we now have a mature, state-of-the-art technology that enables a major leap in the accuracy and stability of network timing while providing a substantially longer lifetime,” said Gil Biran, GM of Oscilloquartz, ADVA. ”From 5G mobile services to mission-critical defense applications, our OSA 3300-HP will be a truly disruptive enhancement of our aPNT+™ technology. And what makes its arrival so significant is that it comes at a moment when existing synchronization solutions in fixed, wireless and cable networks are being stretched to the limit, while the threat of GNSS cyberattacks also continues to grow. Across a wide range of industries, our high-performance cesium atomic clock will meet new timing demands, create new value and open up new possibilities for PNT assurance in critical infrastructure.”
Atomic clocks offer the ultimate synchronization backup for networks that rely on GNSS-based timing, combining high accuracy with outstanding availability. Offering performance that far exceeds best-in-class magnetic cesium devices, the OSA 3300-HP is the industry’s first commercial high-performance optical cesium atomic clock. Featuring an all-digital design, it leverages optical-pumping techniques using laser diodes. This enables it to measure 100 times the number of atoms, making it radically more efficient compared to existing primary reference clock (PRC) technologies. Its product lifespan is 100% longer than competing high-performance magnetic cesium clocks; the OSA 3300-HP delivers optimum stability for over 10 years. What’s more, further to the launch of the OSA 3300-HP, ADVA is also announcing a dual-purpose enhancement of its OSA 3350 ePRC+. Now, as well as providing phase holdover as part of ePRTC systems, it can be utilized as a free-running frequency source with enhanced standard performance.
“What we’ve accomplished with our optical cesium atomic clock solutions is more than incremental innovation. Industrializing optical pumping techniques was widely considered to be impossible. But that’s what our team has achieved. Now, we’re taking precision timing to the next level, empowering networks with nanosecond accuracy and phenomenal stability,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, ADVA. “As well as meeting new sync requirements, our OSA 3300-HP will help simplify operations with its easy-to-use GUI for intuitive configuration and operation. These devices will support advances in a host of different technology fields. Able to meet the most demanding applications in data centers, financial networks, smart grids, transportation, metrology, scientific research and more, they will also be a foundation for future innovation as we continue to expand the boundaries of possibility for accuracy and stability.”
Learn more about ADVA’s OSA 3300-HP in these slides: https://adva.li/osa-3300-hp-slides.
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
t +44 1904 699 358
t +49 89 890 665 854
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release
IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional
PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release
Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr
Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom